Company intelligence / Profile preview

The Medicines Company

Parsippany, New Jersey, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

The company had multiple marketed products including Angiomax (bivalirudin), Cleviprex (clevidipine), Vabomere, Orbactiv, and Minocin. Their lead pipeline candidate inclisiran showed potent and durable reduction of >50% in LDL-C on top of standard of care with an excellent safety profile in Phase 3 trials.

Therapeutic areas: OtherCardiovascularInfectious Diseases
Modalities: Small moleculesbiologicsinjectable therapies
Industry: Biotech

Drug pipeline

1 asset

meropenem + vaborbactam

Commercial

Indications: Complicated urinary tract infections, Hospital-acquired bacterial pneumonia, Ventilator-associated bacterial pneumonia, Carbapenem-resistant Enterobacteriaceae infections

Partnerships

Alnylam Pharmaceuticals (for inclisiran)

Beyond the preview

Go deeper on The Medicines Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Medicines Company.

Explore the full profile